Selected article for: "clinical trial and epidemic prevention"
Author: Jiang, Hu-Da-Chuan; Tao, Yan-Yang; Jia, Si-Yue; Li, Jing-Xin; Zhu, Feng-Cai
Title: Coronavirus disease 2019 vaccines: landscape of global studies and potential risks
  • Cord-id: cil5q891
  • Document date: 2021_9_5
    • ID: cil5q891
    Snippet: With the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccines in epidemic prevention and public health has become even more obvious than ever. However, the emergence of multiple severe acute respiratory syndrome coronavirus 2 variants worldwide has raised concerns about the effectiveness of current COVID-19 vaccines. Here, we review the characteristics of COVID-19 vaccine candidates in five platforms and the latest clinical trial results of them. In addition,
    Document: With the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccines in epidemic prevention and public health has become even more obvious than ever. However, the emergence of multiple severe acute respiratory syndrome coronavirus 2 variants worldwide has raised concerns about the effectiveness of current COVID-19 vaccines. Here, we review the characteristics of COVID-19 vaccine candidates in five platforms and the latest clinical trial results of them. In addition, we further discuss future directions for the research and development of the next generation of COVID-19 vaccines. We also summarize the serious adverse events reported recently after the large-scale vaccination with the current COVID-19 vaccines, including the thromboembolism caused by the AstraZeneca and Johnson & Johnson vaccines.

    Search related documents:
    Co phrase search for related documents
    • acid vaccine and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acid vaccine and live virus: 1, 2
    • actual number and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • actual number and live virus: 1
    • acute sars cov respiratory syndrome coronavirus and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8
    • acute sars cov respiratory syndrome coronavirus and adjuvant require: 1
    • acute sars cov respiratory syndrome coronavirus and adolescent child: 1, 2, 3, 4
    • acute sars cov respiratory syndrome coronavirus and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute sars cov respiratory syndrome coronavirus and low dose vaccine: 1, 2, 3
    • acute sars cov respiratory syndrome coronavirus and low immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • adenoviral vector and live virus: 1, 2